Search by Drug Name or NDC
NDC 00378-3140-85 Frovatriptan 2.5 mg/1 Details
Frovatriptan 2.5 mg/1
Frovatriptan is a ORAL TABLET, FILM COATED in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Mylan Pharmaceuticals Inc.. The primary component is FROVATRIPTAN SUCCINATE.
MedlinePlus Drug Summary
Frovatriptan is used to treat the symptoms of migraine headaches (severe throbbing headaches that sometimes are accompanied by nausea and sensitivity to sound and light). Frovatriptan is in a class of medications called selective serotonin receptor agonists. It works by narrowing blood vessels around the brain, blocking pain signals from being sent to the brain, and stopping the release of certain natural substances that cause pain, nausea, and other symptoms of migraine. Frovatriptan does not prevent migraine attacks or reduce the number of headaches you have.
Related Packages: 00378-3140-85Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Frovatriptan
Product Information
| NDC | 00378-3140 |
|---|---|
| Product ID | 0378-3140_9b875396-1c45-401f-9faa-8af5d9a28eb5 |
| Associated GPIs | 67406030100320 |
| GCN Sequence Number | 048986 |
| GCN Sequence Number Description | frovatriptan succinate TABLET 2.5 MG ORAL |
| HIC3 | H3F |
| HIC3 Description | ANTIMIGRAINE PREPARATIONS |
| GCN | 14977 |
| HICL Sequence Number | 022988 |
| HICL Sequence Number Description | FROVATRIPTAN SUCCINATE |
| Brand/Generic | Generic |
| Proprietary Name | Frovatriptan |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | frovatriptan |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | TABLET, FILM COATED |
| Route | ORAL |
| Active Ingredient Strength | 2.5 |
| Active Ingredient Units | mg/1 |
| Substance Name | FROVATRIPTAN SUCCINATE |
| Labeler Name | Mylan Pharmaceuticals Inc. |
| Pharmaceutical Class | Serotonin 1b Receptor Agonists [MoA], Serotonin 1d Receptor Agonists [MoA], Serotonin-1b and Serotonin-1d Receptor Agonist [EPC] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA202931 |
| Listing Certified Through | n/a |
Package
Package Images
NDC 00378-3140-85 (00378314085)
| NDC Package Code | 0378-3140-85 |
|---|---|
| Billing NDC | 00378314085 |
| Package | 1 BLISTER PACK in 1 CARTON (0378-3140-85) / 9 TABLET, FILM COATED in 1 BLISTER PACK (0378-3140-32) |
| Marketing Start Date | 2016-04-29 |
| NDC Exclude Flag | N |
| Pricing Information | |
| Price Per Unit | 8.34716 |
| Pricing Unit | EA |
| Effective Date | 2022-11-23 |
| NDC Description | FROVATRIPTAN SUCC 2.5 MG TAB |
| Pharmacy Type Indicator | C/I |
| OTC | N |
| Explanation Code | 1 |
| Classification for Rate Setting | G |
| As of Date | 2022-11-23 |
Standard Product Labeling (SPL)/Prescribing Information SPL 626483a8-a543-4183-99bd-7293767881ad Details
HIGHLIGHTS OF PRESCRIBING INFORMATION
FROVATRIPTAN SUCCINATE tablets, for oral use
Initial U.S. Approval: 2001
INDICATIONS AND USAGE
Frovatriptan succinate tablets are a serotonin (5-HT1B/1D) receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults (1)
Limitations of Use
DOSAGE AND ADMINISTRATION
- •
- 1 tablet taken with fluids. Second tablet may be taken 2 hours after initial dose if headache recurs following initial relief. Total dose not to exceed 3 tablets in any 24-hour period (2)
DOSAGE FORMS AND STRENGTHS
Tablets: 2.5 mg (3)
CONTRAINDICATIONS
- •
- History of coronary artery disease or coronary artery vasospasm (4)
- •
- Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders (4)
- •
- History of stroke, transient ischemic attack, or hemiplegic or basilar migraine (4)
- •
- Peripheral vascular disease (4)
- •
- Ischemic bowel disease (4)
- •
- Uncontrolled hypertension (4)
- •
- Recent (within 24 hours) use of treatment with another 5-HT1 agonist, or an ergotamine-containing medication (4)
- •
- Hypersensitivity to frovatriptan succinate tablets (angioedema and anaphylaxis seen) (4)
WARNINGS AND PRECAUTIONS
- •
- Myocardial ischemia/infarction or Prinzmetal’s angina: Perform cardiac evaluation in patients with multiple cardiovascular risk factors (5.1)
- •
- Arrhythmias: Discontinue frovatriptan succinate tablets if occurs (5.2)
- •
- Chest/throat/neck/jaw pain, tightness, pressure, or heaviness: Generally not associated with myocardial ischemia; evaluate high risk patients for coronary artery disease (5.3)
- •
- Cerebral hemorrhage, subarachnoid hemorrhage, and stroke: Discontinue frovatriptan succinate tablets if occurs (5.4)
- •
- Gastrointestinal ischemic reactions and peripheral vasospastic reactions: Discontinue frovatriptan succinate tablets if occurs (5.5)
- •
- Medication overuse headache: Detoxification may be necessary (5.6)
- •
- Serotonin syndrome: Discontinue frovatriptan succinate tablets if occurs (5.7, 7.3)
ADVERSE REACTIONS
- •
- Most common adverse reactions (≥ 2% and > placebo) were dizziness, headache, paresthesia, dry mouth, dyspepsia, fatigue, hot or cold sensation, chest pain, skeletal pain, and flushing (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact Mylan at 1-877-446-3679 (1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.
Revised: 5/2019
Table Of Contents
FULL PRESCRIBING INFORMATION: CONTENTS*
1 INDICATIONS AND USAGE
2 DOSAGE AND ADMINISTRATION
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
5.1 Myocardial Ischemia, Myocardial Infarction, and Prinzmetal’s Angina
5.2 Arrhythmias
5.3 Chest, Throat, Neck, and Jaw Pain/Tightness/Pressure
5.4 Cerebrovascular Events
5.5 Other Vasospasm Reactions
5.6 Medication Overuse Headache
5.7 Serotonin Syndrome
5.8 Increase in Blood Pressure
5.9 Hypersensitivity Reactions
6 ADVERSE REACTIONS
6.1 Clinical Trials Experience
6.2 Postmarketing Experience
7 DRUG INTERACTIONS
7.1 Ergot-containing Drugs
7.2 5-HT 1B/1D Agonists
7.3 Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
8.2 Lactation
8.4 Pediatric Use
8.5 Geriatric Use
8.6 Patients with Hepatic Impairment
10 OVERDOSAGE
11 DESCRIPTION
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
12.3 Pharmacokinetics
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
14 CLINICAL STUDIES
16 HOW SUPPLIED/STORAGE AND HANDLING
17 PATIENT COUNSELING INFORMATION
- *
- Sections or subsections omitted from the full prescribing information are not listed.
1 INDICATIONS AND USAGE
Frovatriptan succinate tablets are indicated for the acute treatment of migraine with or without aura in adults.
Limitations of Use:
- •
- Use only if a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with frovatriptan succinate tablets, reconsider the diagnosis of migraine before frovatriptan succinate tablets are administered to treat any subsequent attacks.
- •
- Frovatriptan succinate tablets are not indicated for the prevention of migraine attacks.
- •
- Safety and effectiveness of frovatriptan succinate tablets have not been established for cluster headache.
2 DOSAGE AND ADMINISTRATION
Dosing Information: The recommended dose is a single tablet of frovatriptan succinate (frovatriptan 2.5 mg) taken orally with fluids.
If the migraine recurs after initial relief, a second tablet may be taken, providing there is an interval of at least 2 hours between doses. The total daily dose of frovatriptan succinate tablets should not exceed 3 tablets (3 x 2.5 mg per 24-hour period).
There is no evidence that a second dose of frovatriptan succinate tablets is effective in patients who do not respond to a first dose of the drug for the same headache.
The safety of treating an average of more than 4 migraine attacks in a 30-day period has not been established.
3 DOSAGE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
Frovatriptan succinate tablets are contraindicated in patients with:
- •
- Ischemic coronary artery disease (CAD) (e.g., angina pectoris, history of myocardial infarction, or documented silent ischemia), or coronary artery vasospasm, including Prinzmetal’s angina [see Warnings and Precautions (5.1)].
- •
- Wolff-Parkinson-White Syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see Warnings and Precautions (5.2)].
- •
- History of stroke, transient ischemic attack (TIA), or history of hemiplegic or basilar migraine because these patients are at a higher risk of stroke [see Warnings and Precautions (5.4)].
- •
- Peripheral vascular disease [see Warnings and Precautions (5.5)].
- •
- Ischemic bowel disease [see Warnings and Precautions (5.5)].
- •
- Uncontrolled hypertension [see Warnings and Precautions (5.8)].
- •
- Recent use (i.e., within 24 hours) of another 5-HT1 agonist, an ergotamine containing or ergot-type medication such as dihydroergotamine (DHE) or methysergide [see Drug Interactions (7.1, 7.2)].
- •
- Hypersensitivity to frovatriptan succinate (angioedema and anaphylaxis seen) [see Warnings and Precautions (5.9)].
5 WARNINGS AND PRECAUTIONS
5.1 Myocardial Ischemia, Myocardial Infarction, and Prinzmetal’s Angina
Frovatriptan succinate tablets are contraindicated in patients with ischemic or vasospastic CAD. There have been rare reports of serious cardiac adverse reactions, including acute myocardial infarction, occurring within a few hours following administration of frovatriptan succinate tablets. Some of these reactions occurred in patients without known CAD. Frovatriptan succinate tablets may cause coronary artery vasospasm (Prinzmetal’s angina), even in patients without a history of CAD.
Perform a cardiovascular evaluation in triptan-naïve patients who have multiple cardiovascular risk factors (e.g., increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD) prior to receiving frovatriptan succinate tablets. Do not administer frovatriptan succinate tablets if there is evidence of CAD or coronary artery vasospasm [see Contraindications (4)]. For patients with multiple cardiovascular risk factors who have a negative cardiovascular evaluation, consider administrating the first frovatriptan succinate tablet dose in a medically-supervised setting and performing an electrocardiogram (ECG) immediately following frovatriptan succinate tablet administration. For such patients, consider periodic cardiovascular evaluation in intermittent long-term users of frovatriptan succinate tablets.
5.2 Arrhythmias
Life-threatening disturbances of cardiac rhythm including ventricular tachycardia and ventricular fibrillation leading to death have been reported within a few hours following the administration of 5-HT1 agonists. Discontinue frovatriptan succinate tablets if these disturbances occur. Frovatriptan succinate tablets are contraindicated in patients with Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders [see Contraindications (4)].
5.3 Chest, Throat, Neck, and Jaw Pain/Tightness/Pressure
Sensations of pain, tightness, pressure, and heaviness have been reported in the chest, throat, neck, and jaw after treatment with frovatriptan succinate tablets and are usually non-cardiac in origin. However, perform a cardiac evaluation if these patients are at high cardiac risk. The use of frovatriptan succinate tablets are contraindicated in patients with CAD and those with Prinzmetal’s angina [see Contraindications (4)].
5.4 Cerebrovascular Events
Cerebral hemorrhage, subarachnoid hemorrhage, stroke, and other cerebrovascular events have been reported in patients treated with 5-HT1 agonists, and some have resulted in fatalities. In a number of cases, it appears possible that the cerebrovascular events were primary, the agonist having been administered in the incorrect belief that the symptoms experienced were a consequence of migraine, when they were not.
Before treating headaches in patients not previously diagnosed as migraineurs, and in migraineurs who present with symptoms atypical of migraine, other potentially serious neurological conditions need to be excluded. Frovatriptan succinate tablets are contraindicated in patients with a history of stroke or TIA [see Contraindications (4)].
5.5 Other Vasospasm Reactions
Frovatriptan succinate tablets may cause non-coronary vasospastic reactions, such as peripheral vascular ischemia, gastrointestinal vascular ischemia and infarction (presenting with abdominal pain and bloody diarrhea), splenic infarction, and Raynaud’s syndrome. In patients who experience symptoms or signs suggestive of a vasospastic reaction following the use of any 5-HT1 agonist, rule out a vasospastic reaction before using frovatriptan succinate tablets [see Contraindications (4)].
Reports of transient and permanent blindness and significant partial vision loss have been reported with the use of 5-HT1 agonists. Since visual disorders may be part of a migraine attack, a causal relationship between these events and the use of 5-HT1 agonists have not been clearly established.
5.6 Medication Overuse Headache
Overuse of acute migraine drugs (e.g., ergotamine, triptans, opioids, or combination of these drugs for 10 or more days per month) may lead to exacerbation of headache (medication overuse headache). Medication overuse headache may present as migraine-like daily headaches or as a marked increase in frequency of migraine attacks. Detoxification of patients, including withdrawal of the overused drugs, and treatment of withdrawal symptoms (which often includes a transient worsening of headache) may be necessary.
5.7 Serotonin Syndrome
Serotonin syndrome may occur with frovatriptan succinate tablets, particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase (MAO) inhibitors [see Drug Interactions (7.3)]. Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination), and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). The onset of symptoms usually occurs within minutes to hours of receiving a new or a greater dose of a serotonergic medication. Discontinue frovatriptan succinate tablets if serotonin syndrome is suspected.
5.8 Increase in Blood Pressure
Significant elevation in blood pressure, including hypertensive crisis with acute impairment of organ systems, has been reported on rare occasions in patients treated with 5-HT1 agonists, including patients without a history of hypertension. Monitor blood pressure in patients treated with frovatriptan succinate tablets. Frovatriptan succinate tablets are contraindicated in patients with uncontrolled hypertension [see Contraindications (4)].
5.9 Hypersensitivity Reactions
There have been reports of reactions, including anaphylaxis and angioedema, in patients receiving frovatriptan succinate tablets. Such reactions can be life threatening or fatal. In general, anaphylactic reactions to drugs are more likely to occur in individuals with a history of sensitivity to multiple allergens. Frovatriptan succinate tablets are contraindicated in patients with a history of hypersensitivity reaction to frovatriptan succinate tablets [see Contraindications (4)].
6 ADVERSE REACTIONS
The following serious adverse reactions are described elsewhere in other sections of the labeling:
- •
- Myocardial Ischemia, Myocardial Infarction, and Prinzmetal’s Angina [see Warnings and Precautions (5.1)]
- •
- Arrhythmias [see Warnings and Precautions (5.2)]
- •
- Chest, Throat, Neck and/or Jaw Pain/Tightness/Pressure [see Warnings and Precautions (5.3)]
- •
- Cerebrovascular Events [see Warnings and Precautions (5.4)]
- •
- Other Vasospasm Reactions [see Warnings and Precautions (5.5)]
- •
- Medication Overuse Headache [see Warnings and Precautions (5.6)]
- •
- Serotonin Syndrome [see Warnings and Precautions (5.7)]
- •
- Increases in Blood Pressure [see Warnings and Precautions (5.8)]
- •
- Hypersensitivity Reactions [see Contraindications (4) and Warnings and Precautions (5.8)]
6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
Frovatriptan succinate tablets were evaluated in four randomized, double-blind, placebo-controlled, short-term trials. These trials involved 2392 patients (1554 on frovatriptan succinate tablets 2.5 mg and 838 on placebo). In these short-term trials, patients were predominately female (88%) and Caucasian (94%) with a mean age of 42 years (range 18 to 69).The treatment-emergent adverse events that occurred most frequently following administration of frovatriptan succinate tablets 2.5 mg (i.e., in at least 2% of patients), and at an incidence ≥ 1% greater than with placebo, were dizziness, paresthesia, headache, dry mouth, fatigue, flushing, hot or cold sensation, dyspepsia, skeletal pain, and chest pain. In a long-term, open-label study where 496 patients were allowed to treat multiple migraine attacks with frovatriptan succinate tablets 2.5 mg for up to 1 year, 5% of patients (n = 26) discontinued due to treatment-emergent adverse events.
Table 1 lists treatment-emergent adverse events reported within 48 hours of drug administration that occurred with frovatriptan succinate tablets 2.5 mg at an incidence of ≥ 2% and more often than on placebo, in the four placebo-controlled trials. The events cited reflect experience gained under closely monitored conditions of clinical trials in a highly selected patient population. In actual clinical practice or in other clinical trials, these incidence estimates may not apply, as the conditions of use, reporting behavior, and the kinds of patients treated may differ.
|
Adverse Reactions |
Frovatriptan |
Placebo
|
|
Central & peripheral nervous system | ||
|
Dizziness |
8% |
5% |
|
Headache |
4% |
3% |
|
Paresthesia |
4% |
2% |
|
Gastrointestinal system disorders | ||
|
Dry mouth |
3% |
1% |
|
Dyspepsia |
2% |
1% |
|
Body as a whole – general disorders | ||
|
Fatigue |
5% |
2% |
|
Hot or cold sensation |
3% |
2% |
|
Chest pain |
2% |
1% |
|
Musculo-skeletal | ||
|
Skeletal pain |
3% |
2% |
|
Vascular | ||
|
Flushing |
4% |
2% |
The incidence of adverse events in clinical trials did not increase when up to 3 doses were used within 24 hours. The incidence of adverse events in placebo-controlled clinical trials was not affected by gender, age, or concomitant medications commonly used by migraine patients. There were insufficient data to assess the impact of race on the incidence of adverse events.
Other Events Observed in Association with the Administration of Frovatriptan Succinate Tablets
The incidence of frequently reported adverse events in four placebo-controlled trials is presented below. Events are further classified within body system categories. Frequent adverse events are those occurring in at least 1/100 patients.
Central and Peripheral Nervous System: dysesthesia and hypoesthesia.
Gastrointestinal: vomiting, abdominal pain and diarrhea.
Body as a Whole: pain.
Psychiatric: insomnia and anxiety.
Respiratory: sinusitis and rhinitis.
Vision Disorders: vision abnormal.
Skin and Appendages: sweating increased.
Hearing and Vestibular Disorders: tinnitus.
Heart Rate and Rhythm: palpitation.
6.2 Postmarketing Experience
The following adverse reactions were identified during post approval use of frovatriptan succinate tablets. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Central and Peripheral Nervous System: Seizure
7 DRUG INTERACTIONS
7.1 Ergot-containing Drugs
Ergot-containing drugs have been reported to cause prolonged vasospastic reactions. Because these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or methysergide) and frovatriptan succinate tablets within 24 hours of each other is contraindicated [see Contraindications (4)].
7.2 5-HT 1B/1D Agonists
Because their vasospastic effects may be additive, co-administration of frovatriptan succinate tablets and other 5-HT1 agonists (e.g., triptans) within 24 hours of each other is contraindicated [see Contraindications (4)].
7.3 Selective Serotonin Reuptake Inhibitors/Serotonin Norepinephrine Reuptake Inhibitors and Serotonin Syndrome
Cases of serotonin syndrome have been reported during combined use of triptans and SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.7)].
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Risk Summary
There are no adequate data on the developmental risk associated with the use of frovatriptan succinate tablets in pregnant women. In animal studies, frovatriptan produced developmental toxicity (embryofetal lethality, fetal abnormalities, and decreased embryofetal growth) when administered to pregnant rats and rabbits at doses greater than those used clinically [see Animal Data].
In the U.S. general population, the estimated background risk of major birth defects and of miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. The reported rate of major birth defects among deliveries to women with migraine ranged from 2.2% to 2.9% and the reported rate of miscarriage was 17%, which were similar to rates reported in women without migraine.
Data
Animal Data
When pregnant rats were administered frovatriptan (oral doses of 0, 100, 500, or 1000 mg/kg/day) throughout organogenesis, increased embryofetal mortality and an increased incidence of fetal malformations were observed at the high dose; decreased fetal body weights and increased incidences of fetal structural variations associated with growth impairment were observed at all doses. The lowest effect dose for embryofetal developmental toxicity in rats (100 mg/kg/day) is approximately 130 times the maximum recommended human dose (MRHD) of 7.5 mg/day on a body surface area (mg/m2) basis.
When pregnant rabbits were administered frovatriptan (oral doses of 0, 5, 20, or 80 mg/kg/day) throughout organogenesis, embryofetal mortality was increased at the mid and high doses. The no-effect dose for embryofetal developmental toxicity in rabbits (5 mg/kg/day) is approximately 13 times the MRHD on a mg/m2 basis.
Oral administration of frovatriptan (0, 100, 500, or 1000 mg/kg/day) to female rats throughout pregnancy and lactation resulted in increased embryofetal mortality at the high dose. The no effect dose for pre- and postnatal developmental toxicity in rats (500 mg/kg/day) is approximately 650 times the MRHD on a mg/m2 basis.
8.2 Lactation
Risk Summary
There are no data on the presence of frovatriptan in human milk, the effects of frovatriptan on the breastfed infant, or the effects of frovatriptan on milk production. In rats, oral dosing with frovatriptan resulted in levels of frovatriptan and/or its metabolites in milk up to four times higher than in plasma.
The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for frovatriptan succinate tablets and any potential adverse effects on the breastfed infant from frovatriptan or from the underlying maternal condition.
8.4 Pediatric Use
The safety and effectiveness in pediatric patients have not been established. Therefore, frovatriptan succinate tablets are not recommended for use in patients under 18 years of age. There are no additional adverse reactions identified in pediatric patients based on postmarketing experience that were not previously identified in adults.
8.5 Geriatric Use
Mean blood concentrations of frovatriptan in elderly patients were 1.5 to 2 times higher than those seen in younger adults [see Clinical Pharmacology (12.3)]. No dosage adjustment is necessary.
8.6 Patients with Hepatic Impairment
No dosage adjustment is necessary when frovatriptan succinate tablets are given to patients with mild to moderate hepatic impairment.
There is no clinical or pharmacokinetic experience with frovatriptan succinate tablets in patients with severe hepatic impairment. Because a greater than two-fold increase in AUC is predicted in patients with severe hepatic impairment, there is a greater potential for adverse events in these patients, and frovatriptan succinate tablets should therefore be used with caution in that population.
10 OVERDOSAGE
The elimination half-life of frovatriptan is 26 hours [see Clinical Pharmacology (12.3)]. Therefore, monitoring of patients after overdose with frovatriptan should continue for at least 48 hours or while symptoms or signs persist. There is no specific antidote to frovatriptan. It is unknown what effect hemodialysis or peritoneal dialysis has on the serum concentrations of frovatriptan.
11 DESCRIPTION
Frovatriptan succinate tablets contain frovatriptan succinate, a selective 5-hydroxy-tryptamine1 (5-HT1B/1D) receptor subtype agonist (triptan), as the active ingredient. Frovatriptan succinate is chemically designated as (3R)-2,3,4,9-Tetrahydro-3-(methylamino)-1H-carbazole-6-carboxamide succinate monohydrate and it has the following structure:
The molecular formula is C14H17N3O•C4H6O4•H2O, representing a molecular weight of 379.41. Frovatriptan succinate is a white to off-white powder that is soluble in water.
Each frovatriptan succinate tablet for oral administration contains 3.91 mg frovatriptan succinate, equivalent to 2.5 mg of frovatriptan base. Each tablet also contains the inactive ingredients anhydrous lactose, colloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, sodium starch glycolate (potato) and titanium dioxide.
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
Frovatriptan binds with high affinity to 5-HT1B/1D receptors. The therapeutic activity of frovatriptan succinate tablets is thought to be due to the agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels (including the arterio-venous anastomoses) and sensory nerves of the trigeminal system which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.
12.3 Pharmacokinetics
The pharmacokinetics of frovatriptan are similar in migraine patients and healthy subjects.
Absorption
Mean maximum blood concentrations (Cmax) in patients are achieved approximately 2 to 4 hours after administration of a single oral dose of frovatriptan 2.5 mg. The absolute bioavailability of an oral dose of frovatriptan 2.5 mg in healthy subjects is about 20% in males and 30% in females. Food has no significant effect on the bioavailability of frovatriptan, but delays tmax by one hour.
Distribution
Binding of frovatriptan to serum proteins is low (approximately 15%). Reversible binding to blood cells at equilibrium is approximately 60%, resulting in a blood: plasma ratio of about 2:1 in both males and females. The mean steady state volume of distribution of frovatriptan following intravenous administration of 0.8 mg is 4.2 L/kg in males and 3.0 L/kg in females.
Metabolism
In vitro, cytochrome P450 1A2 appears to be the principal enzyme involved in the metabolism of frovatriptan. Following administration of a single oral dose of radiolabeled frovatriptan 2.5 mg to healthy male and female subjects, 32% of the dose was recovered in urine and 62% in feces. Radiolabeled compounds excreted in urine were unchanged frovatriptan, hydroxylated frovatriptan, N-acetyl desmethyl frovatriptan, hydroxylated N-acetyl desmethyl frovatriptan and desmethyl frovatriptan, together with several other minor metabolites. Desmethyl frovatriptan has lower affinity for 5-HT1B/1D receptors compared to the parent compound. The N-acetyl desmethyl metabolite has no significant affinity for 5-HT receptors. The activity of the other metabolites is unknown.
Elimination
After an intravenous dose, mean clearance of frovatriptan was 220 and 130 mL/min in males and females, respectively. Renal clearance accounted for about 40% (82 mL/min) and 45% (60 mL/min) of total clearance in males and females, respectively. The mean terminal elimination half-life of frovatriptan in both males and females is approximately 26 hours.
Special Populations
Hepatic Impairment
The AUC of frovatriptan in patients with mild (Child-Pugh 5-6) to moderate (Child-Pugh 7-9) hepatic impairment was about twice that of young, healthy subjects, but within the range observed in healthy elderly subjects and was considerably lower than the values attained with higher doses of frovatriptan (up to 40 mg), which were not associated with any serious adverse effects. There is no clinical or pharmacokinetic experience with frovatriptan succinate tablets in patients with severe hepatic impairment.
Renal Impairment
The pharmacokinetics of frovatriptan following a single oral dose of 2.5 mg was not different in patients with renal impairment (5 males and 6 females, creatinine clearance 16 - 73 mL/min) compared to subjects with normal renal function.
Age
Mean AUC of frovatriptan was 1.5- to 2-fold higher in healthy elderly subjects (age 65 to 77 years) compared to those in healthy younger subjects (age 21 to 37 years). There was no difference in tmax or t1/2 between the two populations.
Drug Interaction Studies
Frovatriptan is not an inhibitor of human monoamine oxidase (MAO) enzymes or cytochrome P450 (isozymes 1A2, 2C9, 2C19, 2D6, 2E1, 3A4) in vitro at concentrations up to 250- to 500-fold higher than the highest blood concentrations observed in man at a dose of 2.5 mg. No induction of drug metabolizing enzymes was observed following multiple dosing of frovatriptan to rats or on addition to human hepatocytes in vitro. Although no clinical trials have been performed, it is unlikely that frovatriptan will affect the metabolism of co-administered drugs metabolized by these mechanisms.
Oral Contraceptives
Retrospective analysis of pharmacokinetic data from females across trials indicated that the mean Cmax and AUC of frovatriptan are 30% higher in those subjects taking oral contraceptives compared to those not taking oral contraceptives.
Ergotamine
The AUC and Cmax of frovatriptan (2 x 2.5 mg dose) were reduced by approximately 25% when co-administered with ergotamine tartrate [see Contraindications (4), Drug Interactions (7.1)].
Propranolol
Propranolol increased the AUC of frovatriptan 2.5 mg in males by 60% and in females by 29%. The Cmax of frovatriptan was increased 23% in males and 16% in females in the presence of propranolol. The tmax as well as half-life of frovatriptan, though slightly longer in the females, were not affected by concomitant administration of propranolol.
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Carcinogenesis
The carcinogenic potential of orally administered frovatriptan was evaluated in an 84-week study in mice (4, 13, and 40 mg/kg/day), a 104-week study in rats (8.5, 27, and 85 mg/kg/day), and a 26-week study in p53(+/-) transgenic mice (20, 62.5, 200, and 400 mg/kg/day). Although a maximum tolerated dose was not achieved in the 84-week mouse study and in female rats, plasma exposures at the highest doses studied were higher than that achieved in humans at the MRHD of 7.5 mg/day. There were no increases in tumor incidence in the 84-week mouse study at doses producing plasma exposures (AUC) 140 times that in humans at the MRHD. In the rat study, there was a statistically significant increase in the incidence of pituitary adenomas in males only at 85 mg/kg/day, a dose associated with a plasma AUC 250 times that in humans at the MRHD. In the 26-week p53(+/-) transgenic mouse study, the incidence of subcutaneous sarcomas was increased in females at doses of 200 and 400 mg/kg/day.
These sarcomas were associated with subcutaneously implanted animal identification transponders, and are not considered to be relevant to humans. There were no other increases in tumor incidence of any type in any dose group.
Mutagenesis
Frovatriptan was clastogenic in human lymphocyte cultures, in the absence of metabolic activation. In the bacterial reverse mutation assay (Ames test), frovatriptan produced an equivocal response in the absence of metabolic activation. Frovatriptan was negative in an in vitro mouse lymphoma tk assay and an in vivo mouse bone marrow micronucleus test.
Impairment of Fertility
Male and female rats were dosed orally with frovatriptan prior to and during mating and in females up to implantation, at doses of 100, 500, and 1000 mg/kg/day (equivalent to approximately 130, 650, and 1300 times the MRHD on a mg/m2 basis). At all dose levels, there was an increase in the number of females that mated on the first day of pairing compared to control animals. This occurred in conjunction with a prolongation of the estrous cycle. In addition, females had a decreased mean number of corpora lutea, and consequently a lower number of live fetuses per litter, which suggested a partial impairment of ovulation. There were no other fertility-related effects.
14 CLINICAL STUDIES
The efficacy of frovatriptan succinate tablets in the acute treatment of migraine headaches was demonstrated in four randomized, double-blind, placebo-controlled, short-term outpatient trials. In these trials, patients received doses of frovatriptan from 0.5 mg to 40 mg. In these controlled short-term trials, patients were predominately female (88%) and Caucasian (94%) with a mean age of 42 years (range 18 to 69). Patients were instructed to treat a moderate to severe headache. Headache response, defined as a reduction in headache severity from moderate or severe pain to mild or no pain, was assessed for up to 24 hours after dosing. The associated symptoms nausea, vomiting, photophobia, and phonophobia were also assessed. Maintenance of response was assessed for up to 24 hours post dose. In two of the trials a second dose of frovatriptan succinate tablets were provided after the initial treatment, to treat recurrence of the headache within 24 hours. Other medication, excluding other 5-HT1 agonists and ergotamine containing compounds, was permitted from 2 hours after the first dose of frovatriptan succinate tablets. The frequency and time to use of additional medications were also recorded.
In all four placebo-controlled trials, the percentage of patients achieving a headache response 2 hours after treatment was significantly greater for those taking frovatriptan succinate tablets 2.5 mg compared to those taking placebo (Table 2).
Lower doses of frovatriptan (1 mg or 0.5 mg) were not effective at 2 hours. Higher doses (5 mg to 40 mg) of frovatriptan showed no added benefit over 2.5 mg but did cause a greater incidence of adverse events.
|
Study |
Frovatriptan |
Placebo |
|
1 |
42%† (n = 90) |
22% (n = 91) |
|
2 |
39%† (n = 187) |
21% (n = 99) |
|
3 |
46%‡ (n = 672) |
27% (n = 347) |
|
4 |
37%‡ (n = 438) |
23% (n = 225) |
The estimated probability of achieving an initial headache response by 2 hours following treatment is depicted in Figure 1.
Figure 1 shows a Kaplan-Meier plot of the probability over time of obtaining headache response (no or mild pain) following treatment with frovatriptan succinate tablets 2.5 mg or placebo. The probabilities displayed are based on pooled data from the four placebo-controlled trials described in Table 2. Patients who did not achieve a response were censored at 24 hours.
In patients with migraine-associated nausea, photophobia, and phonophobia at baseline there was a decreased incidence of these symptoms in frovatriptan succinate tablet-treated patients compared to placebo.
The estimated probability of patients taking a second dose or other medication for their migraine over the 24 hours following the initial dose of study treatment is summarized in Figure 2.
Figure 2: Estimated Probability of Patients Taking a Second Dose or Other Medication for Migraine Over the 24 Hours Following the Initial Dose of Study Treatment
Figure 2 is a Kaplan-Meier plot showing the probability of patients taking a second dose or other medication for migraine over the 24 hours following the initial dose of study medication based on the data from the four placebo-controlled trials described in Table 2. The plot includes those patients who had a response to the initial dose and those who did not. The protocols did not permit remedication within 2 hours of the initial dose.
Efficacy was unaffected by a history of aura; gender; age, or concomitant medications commonly used by migraine patients.
16 HOW SUPPLIED/STORAGE AND HANDLING
Frovatriptan Succinate Tablets are available containing 3.91 mg of frovatriptan succinate equivalent to 2.5 mg of frovatriptan.
The 2.5 mg tablets are white to off-white, film-coated, round, unscored tablets debossed with M on one side of the tablet and FR over 2.5 on the other side. They are available as follows:
NDC 0378-3140-85
carton of 9 unit-dose tablets (1 x 9)
Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]
Protect from moisture.
Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.
17 PATIENT COUNSELING INFORMATION
Advise the patient to read the FDA-approved patient labeling (Patient Information)
Myocardial Ischemia and/or Infarction, Prinzmetal’s Angina, Other Vasospastic Reactions, and Cerebrovascular Events: Inform patients that frovatriptan succinate tablets may cause serious cardiovascular adverse reactions such as myocardial infarction or stroke, which may result in hospitalization and even death. Although serious cardiovascular reactions can occur without warning symptoms, instruct patients to be alert for the signs and symptoms of chest pain, shortness of breath, weakness, slurring of speech, and instruct them to ask for medical advice when observing any indicative sign or symptoms. Instruct patients to seek medical advice if they have symptoms of other vasospastic reactions [see Warnings and Precautions (5.1, 5.2, 5.4, 5.5, and 5.8)].
Hypersensitivity Reactions: Inform patients that anaphylactic reactions have occurred in patients receiving frovatriptan succinate tablets. Inform patients that such reactions can be life threatening or fatal and to seek immediate medical attention if they have anaphylactic symptoms. In general, anaphylactic reactions to drugs are more likely to occur in individuals with a history of sensitivity to multiple allergens [see Contraindications (4)].
Medication Overuse Headache: Inform patients that use of drugs to treat acute migraines for 10 or more days per month may lead to an exacerbation of headache, and encourage patients to record headache frequency and drug use (e.g., by keeping a headache diary) [see Warnings and Precautions (5.6)].
Serotonin Syndrome: Inform patients about the risk of serotonin syndrome with the use of frovatriptan succinate tablets or other triptans, particularly during combined use with SSRIs, SNRIs, TCAs, and MAO inhibitors [see Warnings and Precautions (5.7) and Drug Interactions (7.3)].
Pregnancy: Advise patients to notify their healthcare provider if they become pregnant during treatment or plan to become pregnant [see Use in Specific Populations (8.1)].
Lactation: Inform patients to notify their healthcare provider if they are breastfeeding or plan to breastfeed [see Use in Specific Populations (8.2)].
PATIENT INFORMATION
|
Frovatriptan Succinate Tablets (froe″ va trip′ tan sux′ i nate) |
|
|
What is the most important information I should know about frovatriptan succinate tablets? Frovatriptan succinate tablets can cause serious side effects, including:
Frovatriptan succinate tablets are not for people with risk factors for heart disease unless a heart exam is done and shows no problem. You have a higher risk for heart disease if you: |
|
|
|
|
What are frovatriptan succinate tablets? Frovatriptan succinate tablets are a prescription medicine used to treat migraine headaches with or without aura in adults. Frovatriptan succinate tablets are not used to treat other types of headaches. Frovatriptan succinate tablets are not used to prevent or decrease the number of migraine headaches. It is not known if frovatriptan succinate tablets are safe and effective to treat cluster headaches. It is not known if frovatriptan succinate tablets are safe and effective in children under 18 years of age. |
|
|
Who should not take frovatriptan succinate tablets? Do not take frovatriptan succinate tablets if you have:
Ask your healthcare provider if you are not sure if your medicine is listed above.
|
|
|
What should I tell my doctor before taking frovatriptan succinate tablets? Before taking frovatriptan succinate tablets, tell your doctor about all of your medical conditions, including if you:
Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Frovatriptan succinate tablets and certain other medicines can affect each other, causing serious side effects. Especially tell your doctor if you take:
Ask your doctor or pharmacist for a list of these medicines if you are not sure. Know the medicines you take. Keep a list of them to show your doctor or pharmacist when you get a new medicine. |
|
|
How should I take frovatriptan succinate tablets?
|
|
|
What should I avoid while taking frovatriptan succinate tablets? Frovatriptan succinate tablets can cause dizziness, weakness, or drowsiness. If you have these symptoms do not drive a car, use machinery, or do anything where you need to be alert. |
|
|
What are the possible side effects of frovatriptan succinate tablets? Frovatriptan succinate tablets can cause serious side effects. See “What is the most important information I should know about frovatriptan succinate tablets?”
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The most common side effects of frovatriptan succinate tablets are: |
|
|
|
|
These are not all the possible side effects of frovatriptan succinate tablets. For more information, ask your doctor or pharmacist.
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. |
|
|
How should I store frovatriptan succinate tablets?
Keep frovatriptan succinate tablets and all medicines out of the reach of children. |
|
|
General information about the safe and effective use of frovatriptan succinate tablets. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use frovatriptan succinate tablets for a condition for which they were not prescribed. Do not give frovatriptan succinate tablets to other people, even if they have the same symptoms that you have. They may harm them. You can ask your doctor or pharmacist for information about frovatriptan succinate tablets that is written for health professionals. |
|
|
What are the Ingredients in frovatriptan succinate tablets? Active ingredient: frovatriptan succinate Inactive ingredients: anhydrous lactose, colloidal silicon dioxide, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, sodium starch glycolate (potato) and titanium dioxide Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A. Manufactured by: Mylan Laboratories Limited, Hyderabad – 500 096, India The brands listed are trademarks of their respective owners.
For more information, call Mylan at 1-877-446-3679 (1-877-4-INFO-RX). |
|
This Patient Information has been approved by the U.S. Food and Drug Administration.
Manufactured for:
Mylan Pharmaceuticals Inc.
Morgantown, WV 26505 U.S.A.
Manufactured by:
Mylan Laboratories Limited
Hyderabad — 500 096, India
Revised: 5/2019
75067631
MX:FRVTPS:R2U
PRINCIPAL DISPLAY PANEL – 2.5 mg
NDC 0378-3140-85
Frovatriptan Succinate
Tablets
2.5 mg
Rx only 9 Unit-dose Tablets (1 Card x 9 Tablets)
Each film-coated tablet contains 3.91 mg of frovatriptan succinate
equivalent to 2.5 mg of frovatriptan.
Usual Dosage: See accompanying prescribing information.
Keep this and all medication out of the reach of children.
Store at 20° to 25°C (68° to 77°F).
[See USP Controlled Room Temperature.]
Protect from moisture.
Do not use if blisters are torn, broken or missing.
Manufactured for:
Mylan Pharmaceuticals Inc.
Morgantown, WV 26505 U.S.A.
Made in India
Mylan.com
MX:3140:9C:R2
Code No.: MH/DRUGS/25/NKD/89
INGREDIENTS AND APPEARANCE
| FROVATRIPTAN
frovatriptan tablet, film coated |
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
|
||||||||||||||||||||
| Labeler - Mylan Pharmaceuticals Inc. (059295980) |